Aldeyra Therapeutics Company Profile (NASDAQ:ALDX)

About Aldeyra Therapeutics

Aldeyra Therapeutics logoAldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALDX
  • CUSIP:
Key Metrics:
  • Previous Close: $4.95
  • 50 Day Moving Average: $5.21
  • 200 Day Moving Average: $5.80
  • 52-Week Range: $6,245,000.00 - $3.52
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.67
  • P/E Growth: 0.00
  • Market Cap: $75.43B
  • Outstanding Shares: 6,245,000
  • Beta: 0.41
Profitability:
  • Return on Equity: -73.19%
  • Return on Assets: -64.74%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 11.07%
  • Quick Ratio: 11.07%
Additional Links:
Companies Related to Aldeyra Therapeutics:

Analyst Ratings

Consensus Ratings for Aldeyra Therapeutics (NASDAQ:ALDX) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.33 (220.26% upside)

Analysts' Ratings History for Aldeyra Therapeutics (NASDAQ:ALDX)
Show:
DateFirmActionRatingPrice TargetDetails
12/25/2016Canaccord GenuitySet Price TargetBuy$15.00View Rating Details
11/18/2016HC WainwrightReiterated RatingBuyView Rating Details
11/15/2016Cowen and CompanyReiterated RatingBuyView Rating Details
7/1/2016Stifel NicolausInitiated CoverageBuy$16.00View Rating Details
2/29/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details
3/25/2015Chardan CapitalInitiated CoverageBuy$16.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Aldeyra Therapeutics (NASDAQ:ALDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2017        
11/14/2016Q316($0.39)($0.38)ViewN/AView Earnings Details
8/10/2016Q216($0.44)($0.41)ViewListenView Earnings Details
5/9/2016Q116($0.50)($0.51)ViewN/AView Earnings Details
3/30/2016Q415($0.32)($0.46)ViewListenView Earnings Details
11/12/2015Q315($0.29)($0.35)ViewListenView Earnings Details
8/11/2015Q215($0.35)($0.27)ViewListenView Earnings Details
5/13/2015Q115($0.39)($0.32)ViewListenView Earnings Details
4/14/2015($0.39)($0.31)ViewN/AView Earnings Details
3/19/2015($0.40)($0.30)ViewN/AView Earnings Details
11/10/2014Q314($0.32)($0.36)ViewN/AView Earnings Details
8/4/2014Q214($0.53)($1.56)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)
Current Year EPS Consensus Estimate: $-1.92 EPS
Next Year EPS Consensus Estimate: $-1.91 EPS

Dividends

Dividend History for Aldeyra Therapeutics (NASDAQ:ALDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aldeyra Therapeutics (NASDAQ:ALDX)
Insider Ownership Percentage: 28.40%
Institutional Ownership Percentage: 48.60%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/14/2017Perceptive Advisors LlcMajor ShareholderBuy893,025$4.50$4,018,612.50View SEC Filing  
5/26/2016Perceptive Advisors LlcMajor ShareholderBuy700,000$5.00$3,500,000.00View SEC Filing  
10/26/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.46$323,000.00View SEC Filing  
10/22/2015Perceptive Advisors LlcMajor ShareholderBuy18,020$6.47$116,589.40View SEC Filing  
10/20/2015Perceptive Advisors LlcMajor ShareholderBuy37,145$6.39$237,356.55View SEC Filing  
8/7/2014Martin Joseph JoyceDirectorBuy1,000$3.95$3,950.00View SEC Filing  
8/6/2014C. Boyd ClarkeDirectorBuy3,000$3.69$11,070.00View SEC Filing  
5/7/2014C. Boyd ClarkeDirectorBuy12,500$8.00$100,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aldeyra Therapeutics (NASDAQ:ALDX)
DateHeadline
us.rd.yahoo.com logoAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (NASDAQ:ALDX)
us.rd.yahoo.com - February 18 at 3:26 PM
finance.yahoo.com logoAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters ... - Yahoo Finance (NASDAQ:ALDX)
finance.yahoo.com - February 18 at 7:59 AM
4-traders.com logoALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:ALDX)
www.4-traders.com - February 16 at 8:07 AM
streetinsider.com logoAldeyra Therapeutics (ALDX) Prices 2.2M Offering of Common Stock at $4.50/Share (NASDAQ:ALDX)
www.streetinsider.com - February 14 at 9:06 PM
us.rd.yahoo.com logoAldeyra Therapeutics, Inc. Prices Public Offering of Common Stock (NASDAQ:ALDX)
us.rd.yahoo.com - February 14 at 9:06 PM
News IconMeasuring the Levels on Shares of Aldeyra Therapeutics Inc. (ALDX) - BVN (NASDAQ:ALDX)
bvnewsjournal.com - February 14 at 4:04 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Plans Offering of Common Stock - StreetInsider.com (NASDAQ:ALDX)
www.streetinsider.com - February 14 at 4:04 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Prices 2.2M Offering of Common Stock at $4.50/Share - StreetInsider.com (NASDAQ:ALDX)
www.streetinsider.com - February 14 at 4:04 PM
4-traders.com logoALDEYRA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:ALDX)
www.4-traders.com - February 13 at 8:55 PM
us.rd.yahoo.com logoAldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock (NASDAQ:ALDX)
us.rd.yahoo.com - February 13 at 8:55 PM
us.rd.yahoo.com logo4:02 pm Aldeyra Therapeutics commences common stock offering; size not disclosed (NASDAQ:ALDX)
us.rd.yahoo.com - February 13 at 8:55 PM
News IconAldeyra Therapeutics, Inc. (ALDX) investors have generally offloaded the stock after recent earnings reports - Post Analyst (NASDAQ:ALDX)
postanalyst.com - February 13 at 3:55 PM
News IconStock Review for Aldeyra Therapeutics Inc. (ALDX) - Providence Standard (NASDAQ:ALDX)
providencestandard.com - February 8 at 3:37 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Says First Patient Enrolled in Allergic Conjunctivitis Phase 2b Trial of ADX-102 - StreetInsider.com (NASDAQ:ALDX)
www.streetinsider.com - February 7 at 3:54 PM
finance.yahoo.com logoAldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial (NASDAQ:ALDX)
finance.yahoo.com - February 7 at 3:54 PM
finance.yahoo.com logoAldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day (NASDAQ:ALDX)
finance.yahoo.com - February 6 at 3:30 PM
News IconBrokers Add To Their Ratings On Aldeyra Therapeutics, Inc. (ALDX) - NewsDen (NASDAQ:ALDX)
newsden.net - February 4 at 1:39 AM
News IconTrading Sheet: Tracking Technicals for Aldeyra Therapeutics Inc. (ALDX) - Sherwood Daily (NASDAQ:ALDX)
sherwooddaily.com - February 4 at 1:39 AM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)? - Wall Street Beacon (NASDAQ:ALDX)
wsbeacon.com - February 1 at 3:32 PM
News IconWilliams %R Check on Shares of Aldeyra Therapeutics Inc. (ALDX) - Sherwood Daily (NASDAQ:ALDX)
sherwooddaily.com - January 31 at 8:38 PM
News IconWatching the Levels for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - The Tribune (NASDAQ:ALDX)
lakecitytribune.com - January 31 at 3:36 PM
News IconRelative Strength Index Review on Shares of Aldeyra Therapeutics Inc. (ALDX) - Sherwood Daily (NASDAQ:ALDX)
sherwooddaily.com - January 30 at 8:40 PM
News IconLooking Ahead for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:ALDX)
aikenadvocate.com - January 30 at 3:38 PM
News IconWatching Technical Positions on Aldeyra Therapeutics Inc. (ALDX) - Sherwood Daily (NASDAQ:ALDX)
sherwooddaily.com - January 28 at 3:26 PM
News IconStock Seesawing as Volatility Sweeps in on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Wall Street Beacon (NASDAQ:ALDX)
wsbeacon.com - January 26 at 3:43 PM
nasdaq.com logoELGX Abuzz, ESPR Ahead Of Schedule, Tough Times For VIVO (NASDAQ:ALDX)
www.nasdaq.com - January 26 at 1:37 AM
streetinsider.com logoAldeyra Therapeutics (ALDX) Offers Update on Phase 3 Programs (NASDAQ:ALDX)
www.streetinsider.com - January 26 at 1:37 AM
News IconTrading Indicator Check on Aldeyra Therapeutics Inc. (ALDX) - Sherwood Daily (NASDAQ:ALDX)
sherwooddaily.com - January 25 at 8:35 PM
News IconF-Score in Review on Shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - The Tribune (NASDAQ:ALDX)
lakecitytribune.com - January 25 at 3:32 PM
News IconIs Trouble Brewing For This Stock? Shares Gapping Lower: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Aiken Advocate (NASDAQ:ALDX)
aikenadvocate.com - January 25 at 3:32 PM
News IconEarnings in Full Force, Analysts Take Aim at Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Wall Street Beacon (NASDAQ:ALDX)
wsbeacon.com - January 25 at 3:32 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Offers Update on Phase 3 Programs - StreetInsider.com (NASDAQ:ALDX)
www.streetinsider.com - January 25 at 3:32 PM
finance.yahoo.com logoAldeyra Therapeutics Announces Clinical Development Update for Phase 3 Programs (NASDAQ:ALDX)
finance.yahoo.com - January 25 at 3:32 PM
finance.yahoo.com logo8:02 am Aldeyra Therapeutics anticipates, consistent w/ prior guidance, initiation of its Phase 3 clinical trial in noninfectious anterior uveitis in 2Q17, and initiation of its Phase 3 clinical trial in Sjgren-Larsson Syndrome in the secon (NASDAQ:ALDX)
finance.yahoo.com - January 25 at 3:32 PM
biz.yahoo.com logoALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ALDX)
biz.yahoo.com - January 25 at 3:32 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Prospect Journal (NASDAQ:ALDX)
prospectjournal.com - January 17 at 10:09 AM
News IconStock Perspective: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Company Earnings Watch - Aiken Advocate (NASDAQ:ALDX)
aikenadvocate.com - January 16 at 11:45 AM
News IconCan This Stock Gain Traction: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Prospect Journal (NASDAQ:ALDX)
prospectjournal.com - January 3 at 6:50 AM
News IconReady for an Upsurge? Analysts Chime in on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Prospect Journal (NASDAQ:ALDX)
prospectjournal.com - December 27 at 6:40 AM
News IconReviewing Individual Broker Targets Of Aldeyra Therapeutics, Inc. (ALDX) - NewsDen (NASDAQ:ALDX)
newsden.net - December 20 at 9:01 AM
News IconUpside Alert: Delving into Shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Prospect Journal (NASDAQ:ALDX)
prospectjournal.com - December 20 at 9:01 AM
News IconCCI, ADX, and Williams %R Review for Aldeyra Therapeutics Inc. (ALDX) - Yankee Analysts (NASDAQ:ALDX)
yankeeanalysts.com - December 17 at 3:28 PM
insidermonkey.com logoIs Carolina Bank Holding Inc. (NC) (CLBH) A Good Stock To Buy? (NASDAQ:ALDX)
www.insidermonkey.com - December 15 at 3:52 PM
News IconLooking at the Technicals for Aldeyra Therapeutics Inc. (ALDX) - Yankee Analysts (NASDAQ:ALDX)
yankeeanalysts.com - December 8 at 3:37 PM
News IconRelative Strength Index Review on Shares of Aldeyra Therapeutics Inc. (ALDX) - Yankee Analysts (NASDAQ:ALDX)
yankeeanalysts.com - December 6 at 8:35 PM
capitalcube.com logoAldeyra Therapeutics, Inc. :ALDX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016 (NASDAQ:ALDX)
www.capitalcube.com - December 5 at 4:14 PM
News IconTechnical Investor Update on Shares of Aldeyra Therapeutics Inc. (ALDX) - StockTalk Daily (NASDAQ:ALDX)
stocktalkdaily.com - December 4 at 6:57 AM
News IconMA in Focus for Aldeyra Therapeutics Inc. (ALDX) - Yankee Analysts (NASDAQ:ALDX)
yankeeanalysts.com - December 3 at 3:24 PM
News IconChecking in on Signals for Aldeyra Therapeutics Inc. (ALDX) - Yankee Analysts (NASDAQ:ALDX)
yankeeanalysts.com - November 23 at 3:26 PM
News IconUpdate on Valuation Formula's For Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Wall Street Lion (NASDAQ:ALDX)
wslnews.com - November 23 at 12:19 PM

Social

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Where is Aldeyra Therapeutics' stock going? Where will Aldeyra Therapeutics' stock price be in 2017?

5 analysts have issued 1-year price targets for Aldeyra Therapeutics' stock. Their predictions range from $15.00 to $18.00. On average, they expect Aldeyra Therapeutics' share price to reach $16.33 in the next twelve months.

When will Aldeyra Therapeutics announce their earnings?

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.

Who owns Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (31.07%), FMR LLC (28.79%) and Boxer Capital LLC (4.66%).

Who bought Aldeyra Therapeutics stock? Who is buying Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC.

How do I buy Aldeyra Therapeutics stock?

Shares of Aldeyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aldeyra Therapeutics stock cost?

One share of Aldeyra Therapeutics stock can currently be purchased for approximately $5.10.

Aldeyra Therapeutics (NASDAQ:ALDX) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Earnings History Chart

Earnings by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Dividend History Chart

Dividend Payments by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Last Updated on 2/19/2017 by MarketBeat.com Staff